National Vision Holdings, Inc. (EYE) is winning market shares across four sub segments of the Owned and Host. The company is also advancing its transformation efforts with continued expansion of exam capacity, new traffic-driving initiatives and initiatives to strengthen its business foundation for profitable growth. Additionally, National Vision will also capitalize on the favorable trends within the U.S. optical retail industry, which is encouraging. Meanwhile, the mounting expenses and high dependence on ...

I wrote about National Vision Holdings (NASDAQ: EYE ) previously (31 st May) with a buy rating as I expected EYE to be at the high end of its FY24 guidance, and whenI am an individual investor that is now fully focus on managing my own capital that I have saved up over the years. My investing background spreads across a wide spectrum as I believe there are merits to each approach, for instance: Fundamental investing [Bottoms-up etc.], Technical investing [historical charts analysis], and to some extend mome ...

Earnings Performance - Adjusted EPS for Q3 2024 was 12 cents, surpassing the Zacks Consensus Estimate of 5 cents and up from 11 cents in the year-ago period [1] - GAAP income from continuing operations was 3 cents per share, down from 23 cents in the prior-year quarter [1] - Shares of EYE dropped 3.1% following the earnings announcement, closing at $11.82 [2] Revenue Performance - Q3 2024 net revenues from continuing operations totaled $451.5 million, missing the Zacks Consensus Estimate by 0.03% [3] - Top line rose 2.9% year-over-year, driven by new store sales, Adjusted Comparable Store Sales Growth, and unearned revenues [4] - Comparable store sales growth was 1.4% year-over-year, with adjusted comparable store sales growth at 0.9% [4] - The company opened 18 new stores, ending the quarter with 1,231 stores, a 4.9% year-over-year increase in store count [4] Margin Performance - Gross profit in Q3 2024 rose 2.6% year-over-year to $261.6 million, with gross margin expanding 110 basis points despite a 3.3% rise in cost of revenues [5] - SG&A expenses fell 1.6% year-over-year to $224 million [5] - Adjusted operating margin expanded 207 basis points year-over-year to 8.3% [5] Financial Position - Cash and cash equivalents at the end of Q3 2024 were $81.2 million, down from $179.5 million at the end of Q2 2024 [6] - Cumulative net cash flow from operating activities was $103.4 million, compared to $153.3 million a year ago [6] 2024 Outlook - Full-year net revenues for 2024 are expected to be in the range of $1.820-$1.840 billion, unchanged from previous guidance [7] - Adjusted comparable store sales are expected to grow 0.5%-1.5%, unchanged from previous guidance [7] - Adjusted EPS for 2024 is estimated to be in the range of 45-50 cents, unchanged from previous guidance [7] Portfolio Review Update - The company identified less than 5% of its total store fleet as not meeting profitability thresholds, with plans to close 39 stores by the end of fiscal 2026 and convert four Eyeglass World stores to America's Best by the end of fiscal 2024 [8] - In fiscal 2025, new store openings will be temporarily moderated to 30-35 stores, with plans to return to a more recent store opening cadence thereafter [9] Business Performance and Strategy - America's Best continued to drive sales performance, supported by strength in the managed care business [10] - Customers responded well to the Wise Buys eyeglass promotion, enhancing value offerings and attracting new customers [11] - The company is leveraging remote capabilities to expand exam capacity and provide doctors with new ways to practice [11] - Progress in transformation initiatives includes the completion of the store fleet review, implementation of new traffic-driving initiatives, expansion of exam capacity, and improved remote exam efficiency [12] Industry Comparison - Haemonetics (HAE) reported Q2 fiscal 2025 adjusted earnings of $1.12 per share, surpassing the Zacks Consensus Estimate by 2.8%, with revenues of $345.5 million beating the consensus mark by 0.7% [14] - Intuitive Surgical (ISRG) posted Q3 2024 EPS of $1.84, beating the Zacks Consensus Estimate by 11.5%, with revenues of $2.04 billion surpassing the consensus estimate by 1.2% [15] - Boston Scientific Corporation (BSX) reported Q3 2024 adjusted earnings of 63 cents per share, surpassing the Zacks Consensus Estimate by 8.6%, with revenues of $4.21 billion beating the consensus estimate by 4.5% [16]

National Vision Holdings, Inc. (NASDAQ:EYE) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Tamara Gonzalez - Vice President, Investor Relations Reade Fahs - Chief Executive Officer Alex Wilkes - President Melissa Rasmussen - Chief Financial Officer Conference Call Participants Michael Lasser - UBS Kate McShane - Goldman Sachs Zachary Fadem - Wells Fargo Jon Elias - BMO Capital Markets Dylan Carden - William Blair Paul Lejuez - Citi Brian Tanquilut - Jefferies Adrienne Yih ...

| --- | --- | |-------|--------------| | | | | | QUARTER 2024 | | | 1 | D I S C L A I M E R Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934. These statements include, but are not limited to, statements contained under "Fiscal 2024 Outlook," as well as other statements related to our current beliefs and expectations regardin ...

National Vision (EYE) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.15 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 140%. A quarter ago, it was expected that this discount optical retailer and eye care provider would post earnings of $0.06 per share when it actually produced earnings of $0.15, delivering a surprise of 150%.Over t ...

Exhibit 99.1 National Vision Holdings, Inc. Reports Third Quarter 2024 Financial Results Results Reflect Ongoing Strength in Managed Care with Growth in America's Best as Transformation Initiatives Progress Third quarter 2024 highlights compared to Q3 2023: • Net revenue from continuing operations of $451.5 million, an increase of 2.9% • Comparable store sales growth of 1.4% and Adjusted Comparable Store Sales Growth of 0.9% • Net loss from continuing operations of $(8.4) million, Diluted EPS from continuin ...

Wall Street expects a year-over-year decline in earnings on lower revenues when National Vision (EYE) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on November 6, 2024, might help the stock move higher if these key numbers are better th ...

National Vision, Inc. (EYE) has strengthened its existing partnership with Pair Eyewear, the first direct-toconsumer and leading customizable eyewear brand, by expanding to all 1,000+ America's Best stores. In addition to forming an exclusive retail partnership, the strategic collaboration establishes the company's Doctor of Optometry network as the popular online brand's official eye care provider. By purchasing an affordable bundle offer that includes one base frame and two top frames, customers can also ...

THOUSAND OAKS, Calif., Sept. 24, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced TEPEZZA® (JAN: Teprotumumab (Genetical Recombination)) has been approved for the treatment of active or high clinical activity score (CAS) Thyroid Eye Disease (TED) by Japan's Ministry of Health, Labour and Welfare (MHLW). PRODUCT NAME TEPEZZA® for Intravenous Infusion 500 mg Generic Name (JAN) Teprotumumab (Genetical Recombination) Indication Active thyroid eye disease Hearing disorders (e.g., deafness, hypoacusis, Eu ...